Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nottingham Trent University currently maintains 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, showing a split in the current prosecution oversight. This distribution suggests that the university is pursuing multiple distinct biological innovations that fall under different technical classifications. The presence of 2 pending office actions indicates an active effort to expand the university's patent portfolio.
The busiest examiner for the company is GODDARD, LAURA B, who is assigned 1 busiest examiner pending office action. With 2 pending office actions assigned to different examiners, the university must manage the individual procedural styles of multiple officials. For a practitioner, this requires a flexible approach, as the arguments that work with one examiner may not be as effective with the other. The success of the portfolio is not tied to a single individual but depends on navigating the requirements of 2 distinct examiners across 2 different art units. Monitoring the progress of both cases will provide a broader view of the university's success in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17290061 | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | SITTON, JEHANNE SOUAYA | 88d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17290061 | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | SITTON, JEHANNE SOUAYA | 88d overdue |
| 18001025 | Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | GODDARD, LAURA B | 22d overdue |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001025 | Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | GODDARD, LAURA B | 1642 | §112 | Final Rejection | 22d overdue | Pending | Dec 07, 2022 |
| 17290061 | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | SITTON, JEHANNE SOUAYA | 1682 | §101 | Final Rejection | 88d overdue | Pending | Apr 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial